A Diverse And Sustainable Compound Library For Aid Drug Development And Sales

This paper hopes to share insight into the steps that are taken by companies, and the strenuous process behind developing an effective new drug.

Extremely risky drug discovery and development, lengthening development times which increase development cost, return on investments, and generic competitors.

In 2007, PPCPs such as diclofenac, iopamidol, musks and carbamazepine were identified as future emerging priority candidates. Ibuprofen, clofibric acid, triclosan, phthalates and bisphenol A are proposed additions to this list [45].

Compounding is an important facet of pharmaceutics that allows the formulation of specific drugs for individual patients. The work done at compounding pharmacies permits the development of medicinal products for patients that cannot tolerate certain components from mass production pharmaceutical companies. These individuals may require uniquely compounded agents to be flavorless, preservative-free, dye-free, liquid, solid, or more. These specialty production facilities are necessary for therapy and an acceptable quality of life for individuals with specific needs. Recently, the patient-driven role of designer therapeutics that compounding pharmacies occupy was overshadowed when a manmade epidemic was produced a medical catastrophe when supposedly sterile materials were contaminated with infectious agents.1

* No foreseeable new product in pipeline. Currently takes up to 11,000 compounds to be screened to find one (1) compound to send through final testing (human trials). And even then it’s not guaranteed to make it past the FDA.

High throughput screening (HTS) is essential in the process of finding a potential drug candidate, and automation is key for a good screen both in terms of robustness and reproducibility.

In America today finding a cure for cancer is a huge priority with clinical trails being a big part in these goal there are some newly developed drugs and technology that are making a huge impact in the cancer world.

Ng, Rick. Drugs: From Discovery to Approval. 3rd ed. Hoboken, NJ: John Wiley & Sons, 2015.

The clinical research market is a very vast and ever changing market. There are continuous evolutions taking place and there are always new products coming into market everyday. Though it takes many years for a drug to come into market there is a continuous research going on. There are advancements taking place continuously in this industry, which is not possible without the main players and stakeholders within the industry. These stake holders range in a broad area which include site management organizations, researchers, developers, regulators, participants, government agencies etc.

The Mission of PhRM is, “To conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical and biotechnology research companies.” [ (PhRMA Reasearch, Progress, Hope Health Coutcomes Reasearch, 2013) ] PhRMA does extensive research on the different medical treatments from a variety of sources. The research

The decrease in the rate at which novel medical products are reaching the market, despite major scientific achievements and investment that might have predicted otherwise, is causing much concern. Although this 'pipeline problem' has often been discussed in the context of drug development, it is also crucial to examine the unique characteristics of the pipeline for biomarkers and diagnostics.

Investigators use different techniques to discover and discover new ways to fight disease with molecules that do not exist in nature. This involves developing synthetic versions, or analogs, of naturally occurring compounds.

Genentech struggled to blaze a trail out of the drug-industry swamp. By the late 1980’s, the company began to show promising results. Genentech had altered its business model toward medicines that enhanced rapid advancements in diagnostics, genomics and biotechnology for personalized medicine. Genentech focused on five therapeutic areas: oncology immunology, neuroscience, metabolism, and infectious diseases (Chatman,

Drug research is connected to a range of academic studies such as biology, pharmacology, medicinal chemistry and toxicology. Pharmaceutical researchers can design novel therapeutic drugs based on these studies above. The invention of new drug can be divided by function into two stages: drug discovery and drug development. Drug discovery is the process by which a new drug candidate is found and identified. Distinctively, bringing a new drug candidate to the market through clinical trials is called drug development. The first part of this essay provides an overview of drug discovery and pre-clinical research and development

3-5 sentence “quick pitch” outlining key takeaways that will be explored in more depth within the body of the profile.